Tirzepatide alleviates doxorubicin-induced cardiotoxicity via inhibiting HRD1-mediated Nrf2 ubiquitination.

Background: Doxorubicin (DOX), an effective and commonly used chemotherapeutic agent, often triggers dosage-dependent and potentially lethal cardiotoxicity, which heavily limits its clinical application in cancer survivors. However, no actual pharmacological therapeutics for this adverse effect are available. Tirzepatide (TZP), a novel GIP/GLP-1 receptor agonist, exhibits efficacy in controlling glycemia and has very recently been approved for the treatment of type 2 diabetes.

[Determination of lornoxicam in human plasma by LC/MS/MS].

Aim: To develop a sensitive and specific LC/MS/MS method for determination of lornoxicam in human plasma and investigate pharmacokinetics of single dose of lornoxicam in healthy Chinese volunteers.

Methods: Lornoxicam and the internal standard piroxicam were extracted from plasma using liquid-liquid extraction, then separated on a Zorbax XDB-C8 column. The mobile phase consisted of methanol-water-formic acid (80:20:0.